WuXi AppTec Unfazed by BIOSECURE Act Threat, Secures New US Deals

BIOSECURE Act Impact:
The BIOSECURE Act aims to restrict US biopharma companies from partnering with Chinese companies like WuXi AppTec due to national security concerns.

WuXi's US Presence:
WuXi AppTec has a significant presence in the US, with over a dozen facilities and a new 190-acre pharmaceutical manufacturing campus in Delaware.

Revenue Performance:
Despite the BIOSECURE Act threat, WuXi AppTec reported a slight drop in US revenue but saw increases in Europe and China.

Lobbying Efforts:
WuXi AppTec has increased its lobbying efforts in the US to address concerns and advocate for changes in the legislation.

Indian CDMOs Opportunity:
The scrutiny on WuXi AppTec could potentially benefit Indian contract development and manufacturing organizations (CDMOs) as they seek to expand their share in the US market.